

Global Insulin Market is Expected to Reach USD 47.54 Billion by 2020

OrbisResearch.com has published new research report on "Global Insulin Market Research Report and Forecast to 2020" to its database.

DALLAS, TEXAS, USA, April 27, 2017 /EINPresswire.com/ -- The [global market for insulin](#) is expected to reach USD 47.54 billion by 2020. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as India and China are expected to be two of the most significant growth drivers of this market. Moreover, increasing incidence rates of lifestyle induced diseases such as obesity and growing global geriatric population base are expected to serve the global insulin market as drivers.



Request a sample of the report: <http://www.orbisresearch.com/contacts/request-sample/60834>

The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares.

Further key findings from the study suggest:

Insulin analogs were the most dominant source in 2013 and accounted for over 70% of the revenue. These products are rapidly substituting the human recombinant insulin products by exhibiting higher efficacy.

Buy the report@<http://www.orbisresearch.com/contact/purchase/60834>

North America was the largest regional market in 2013, accounting for over 40% of global revenue. The presence of sophisticated healthcare infrastructure, high type I diabetes prevalence and patient disposable incomes in this region are some of the factors expected to drive market growth. Emerging markets including Asia Pacific accounted for 26.5% of global revenue in 2013.

Asia Pacific insulin market is expected to grow at the highest CAGR of over 15% from 2014 to 2020 on account of the presence of high unmet medical needs pertaining to diabetes and increasing healthcare expenditures in emerging markets such as India and China. Key industry participants include Sanofi, Novo Nordisk, Eli Lilly, Novartis, Biocon, Oramed Pharmaceuticals, Bristol-Myers Squibb, Takeda Pharmaceuticals, Dongbao Enterprise Group Co., Ltd. and others.

Get the discount: <http://www.orbisresearch.com/contacts/discount/60834>

For the purpose of this study, Grand View Research has segmented the global insulin market on the basis of product, segment (on the basis of source), application and region:

- Insulin Product Outlook
- Fast Acting Insulin
- Short Acting Insulin
- Intermediate Acting Insulin
- Long Acting Insulin
- Pre-Mixed Insulin
- Insulin Segment (on the basis of source) Outlook
- Insulin Analogs
- Human Recombinant Insulin
- Insulin Application Outlook
- Insulin for Type I Diabetes
- Insulin for Type II Diabetes
- Insulin Regional Outlook
- North America
- Europe
- Asia Pacific
- RoW

Major Points From Table Of Contents:

Chapter One: Executive Summary
Chapter Two: Insulin Industry Outlook
Chapter Three: Insulin Product Outlook
Chapter Four: Insulin Segment (on the basis of source) Outlook
Chapter Five: Insulin Application Outlook
Chapter Six: Insulin Regional Outlook
Chapter Seven: Competitive Landscape
Chapter Eight: Methodology and Scope

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research
+1 (214) 884-6817
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/378120566>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.